Eurofins Investor Relations Information for Investors is a valuable resource for those looking to stay informed about the company's financial performance and growth prospects. Eurofins is a global leader in bioanalytical testing, offering a wide range of services to the pharmaceutical, food, environmental, and consumer products industries.
The company's investor relations website provides a wealth of information for investors, including financial reports, presentations, and press releases. Eurofins also hosts investor days and webcasts to keep investors up-to-date on the company's progress.
Regulatory Information
Eurofins is a global leader in bioanalytical testing, with operations in over 50 countries.
The company is listed on the Euronext Paris stock exchange under the ticker symbol ERFP.PA.
Eurofins has a strong track record of meeting or exceeding analyst expectations.
According to the company's most recent annual report, revenue growth has been consistently strong, with a 5-year CAGR of 15%.
Eurofins has a diverse portfolio of services, including bioanalytical testing, product testing, and genomics.
The company has a significant presence in the pharmaceutical and biotechnology industries, with many major clients.
Eurofins has a strong commitment to innovation, with a significant R&D budget and a focus on developing new testing technologies.
The company has a global network of laboratories and testing facilities, providing fast and reliable testing services to clients around the world.
Company Listings
Eurofins shares are listed on Euronext Paris, which is a significant milestone for the company, dating back to its IPO in October 1997.
ISIN FR0014000MR3 is the unique identifier assigned to Eurofins shares, making it easy for investors to track the company's performance.
Euronext ERF is another identifier used to reference Eurofins shares on the Euronext Paris exchange.
Investors can also use Reuters EUFI.PA and Bloomberg ERF FP to access Eurofins share information.
Eurofins shares are part of several major indices, including the CAC 40, EURONEXT 100, and SBF 120, which provides a benchmark for the company's performance in the European market.
Frequently Asked Questions
Why did Eurofins stock drop?
Eurofins stock dropped due to slower research and development activities in the biopharmaceutical sector following the COVID-19 pandemic. This led to a trimmed full-year revenue target, causing the stock to slump.
Who owns Eurofins Scientific?
Gilles Martin owns approximately 25% of Eurofins Scientific through his family's holding company Analytical Bioventures. His family's stake in the company is valued at $5.2 billion.
Is Eurofins an ethical company?
Eurofins Lancaster Laboratories, LLC upholds the highest ethical standards in its business operations. They prioritize social responsibility in all aspects of their work.
Sources
- https://www.eurofins.com/media-centre/safeharborstatement/
- https://quartr.com/companies/eurofins-scientific-se_6249
- https://www.eurofins.com/about-us/our-business/eurofins-fact-sheet/
- https://www.alphaspread.com/security/par/erf/investor-relations
- https://www.alphaspread.com/security/par/alecr/investor-relations
Featured Images: pexels.com
